European Society for Animal Cell Technology (ESACT) 2026
Salzburg, Austria
June 7–10, 2026
Join Genedata experts at the 29th Annual Meeting of ESACT.
Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including cell line design and development, bioprocess optimization, quality control of biologicals, and NGS-based assays for cell line development and biosafety in a GMP environment. Central to this is a unified, AI‑ready digital foundation that structures and connects high‑quality data across R&D and manufacturing, enabling automation, advanced analytics, and predictive insights while ensuring full traceability and regulatory compliance
To get more information about Genedata solutions, please contact info(at)genedata.com.
Recommended Poster Presentations
AI-Driven, GMP-Compliant Digital Infrastructure for NGS-Based Decision-Making in Development and Manufacturing
Presenter: Sarah Berger, Genedata AG, Basel, Switzerland
Advanced analytics are essential for ensuring quality and safety in biopharmaceutical manufacturing, yet NGS adoption across R&D and GMP is hindered by fragmented, non‑interoperable workflows. Genedata Selector® integrates NGS instruments with ELN/LIMS, automates assay development, and consolidates multi‑omics, process, and quality data into a FAIR‑compliant foundation. This unified, AI‑ready data backbone enables compliance, reproducibility, and predictive analytics, bridging research and manufacturing while accelerating and de‑risking advanced therapy development.
NGS as an Analytical Method for Regulatory-Compliant, Automated Monitoring of CQAs in Complex Biologics
Presenter: Christoph Bredack, Genedata AG, Basel, Switzerland
NGS enables assessment of critical quality attributes (CQAs) including identity, integrity, and purity across advanced modalities such as cell and gene therapies, viral vectors, and vaccines, and is increasingly recognized by regulators (ICH Q5A(R2), Ph. Eur. 2.6.41). Genedata Selector® is validation‑ready, software solution for NGS data analysis that automates assays, delivering compliant, traceable reports, reducing error rates and turnaround times. It enables readouts for multiple CQAs accelerating CMC decision‑making in development and GMP settings.
Building an AI‑Ready Bioprocess Organization Needs a Unified Data Backbone
Presenter: Sascha Fischer, Genedata AG, Basel, Switzerland
Bioprocess and CMC development are becoming increasingly complex due to high‑throughput experimentation, siloed data, and rising demands for traceability, compliance, and speed. The Genedata Biopharma Platform provides a unified, enterprise‑scale foundation that structures and contextualizes all bioprocess and CMC data, ensuring full lineage, cross‑functional collaboration, and end‑to‑end compliance. By enabling automated documentation, orchestrated lab workflows, and AI‑ready datasets, it transforms bioprocess development into a digital and computational discipline.
Structured Knowledge Management Platform for Bioprocess Development
Presenter: Fern Slingsby, Genedata Ltd., London, UK
The growing adoption of high‑throughput technologies and laboratory automation has dramatically increased data volumes in bioprocess development. Genedata Bioprocess® is an end‑to‑end structured knowledge management platform supporting diverse modalities, including proteins, nucleic acid therapeutics, and cell and gene therapies. It automates upstream and downstream workflows, supports scale‑up, enables full lineage tracking, and systematically links analytical, process, and material data to drive robust process understanding and quality risk management.